Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 15, Issue 11, Pages 20500-20517
Publisher
MDPI AG
Online
2014-11-07
DOI
10.3390/ijms151120500
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells
- (2014) Lorena Rosik et al. CANCER BIOLOGY & THERAPY
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Targeted polytherapy in small cell sarcoma and its association with doxorubicin
- (2014) S.N. Dumont et al. Molecular Oncology
- Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer
- (2014) Rosário Pinto-Leite et al. TUMOR BIOLOGY
- Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells
- (2014) Hang Yuan WORLD JOURNAL OF GASTROENTEROLOGY
- Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
- (2013) Susanne Krege et al. BJU INTERNATIONAL
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
- (2013) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation
- (2013) Guangwu Guo et al. NATURE GENETICS
- Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
- (2012) M. Rahmani et al. BLOOD
- Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer
- (2012) Simone Fulda EXPERT OPINION ON THERAPEUTIC TARGETS
- Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
- (2011) L. Kretzner et al. CANCER RESEARCH
- Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent
- (2011) Jane L. Hurwitz et al. EUROPEAN JOURNAL OF CANCER
- S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
- (2011) Roman Nawroth et al. PLoS One
- Stress-activated kinase pathway alteration is a frequent event in bladder cancer
- (2011) Kristen B. Otto et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The role of c-FLIP splice variants in urothelial tumours
- (2011) F Ewald et al. Cell Death & Disease
- Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells
- (2010) A Rose et al. BRITISH JOURNAL OF PHARMACOLOGY
- Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation
- (2010) Margaret A. Park et al. CANCER BIOLOGY & THERAPY
- The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs
- (2010) Adrienne D. Cox et al. CANCER CELL
- The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
- (2010) D. Llobet et al. EUROPEAN JOURNAL OF CANCER
- The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib
- (2010) Hayato Hikita et al. HEPATOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
- (2010) Srikala S. Sridhar et al. INVESTIGATIONAL NEW DRUGS
- Expression Signature of E2F1 and Its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors
- (2010) Ju-Seog Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Towards a knowledge-based Human Protein Atlas
- (2010) Mathias Uhlen et al. NATURE BIOTECHNOLOGY
- The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
- (2010) O. E. Sturm et al. Science Signaling
- Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma
- (2010) Shuzhe Yang et al. WORLD JOURNAL OF UROLOGY
- Phase 2 trial of sorafenib in patients with advanced urothelial cancer
- (2009) Robert Dreicer et al. CANCER
- Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
- (2009) Martin Schwickart et al. NATURE
- Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
- (2008) G. Zhang et al. CLINICAL CANCER RESEARCH
- Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells
- (2008) Annick Muhlethaler-Mottet et al. Molecular Cancer
- Bladder cancer subtypes defined by genomic alterations
- (2008) Margaret A. Knowles SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now